Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HELIOS: Bitopertin in Erythropoietic Protoporphyria
NCT05883748Phase 3Enrolling by invitation
- Sponsor
- Disc Medicine
- Start
- Aug 2023
- Primary completion
- Jun 2028
- Modality
- Small Molecules
- Countries
- 11
01
Overview
Phase 3, open-label trial of bitopertin in erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP) (2 arms), sponsored by Disc Medicine. Primary endpoints: Incidence of treatment-emergent adverse events at 5 years, Incidence of clinically abnormal vital signs at 5 years and 4 more. Started Aug 2023; status: enrolling by invitation.
02
Drugs
bitopertin
03
Conditions
erythropoietic protoporphyria (EPP)X-linked protoporphyria (XLP)
Beyond the preview
Go deeper on NCT05883748.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05883748.